Insider Trading Alert - CME, DBD, HK, ATR And ACT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 10, 2013, 123 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $495.90 to $1,382,884,839.00.

Highlighted Stocks Traded by Insiders:

CME Group (CME) - FREE Research Report

Odom C C II who is Director at CME Group sold 500 shares at $79.11 on Dec. 10, 2013. Following this transaction, the Director owned 8,003 shares meaning that the stake was reduced by 5.88% with the 500-share transaction.

The shares most recently traded at $80.03, up $0.92, or 1.15% since the insider transaction. Historical insider transactions for CME Group go as follows:

  • 4-Week # shares sold: 4,093
  • 12-Week # shares bought: 350
  • 12-Week # shares sold: 4,093
  • 24-Week # shares bought: 350
  • 24-Week # shares sold: 10,430

The average volume for CME Group has been 1.6 million shares per day over the past 30 days. CME Group has a market cap of $27.2 billion and is part of the financial sector and financial services industry. Shares are up 57.37% year-to-date as of the close of trading on Tuesday.

CME Group Inc. operates the CME, CBOT, NYMEX COMEX, and KCBT futures exchanges worldwide. It operates CBOT exchange, a marketplace for trading agricultural and the U.S. The stock currently has a dividend yield of 2.22%. The company has a P/E ratio of 28.4. Currently there are 7 analysts that rate CME Group a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CME - FREE

TheStreet Quant Ratings rates CME Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CME Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Diebold Incorporated (DBD) - FREE Research Report

Mattes Andreas W who is President and CEO at Diebold Incorporated bought 500 shares at $32.88 on Dec. 10, 2013. Following this transaction, the President and CEO owned 27,987 shares meaning that the stake was reduced by 1.82% with the 500-share transaction.

The shares most recently traded at $32.18, down $0.70, or 2.16% since the insider transaction. Historical insider transactions for Diebold Incorporated go as follows:

  • 12-Week # shares bought: 200
  • 24-Week # shares bought: 1,200

The average volume for Diebold Incorporated has been 894,100 shares per day over the past 30 days. Diebold Incorporated has a market cap of $2.1 billion and is part of the technology sector and computer software & services industry. Shares are up 5.49% year-to-date as of the close of trading on Tuesday.

Diebold, Incorporated provides integrated self-service delivery and security systems and services primarily to the financial, commercial, government, and retail markets worldwide. The stock currently has a dividend yield of 3.53%. Currently there is 1 analyst that rates Diebold Incorporated a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DBD - FREE

TheStreet Quant Ratings rates Diebold Incorporated as a hold. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Diebold Incorporated Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Halcon Resources (HK) - FREE Research Report

Hunt David S. who is Director at Halcon Resources bought 10,000 shares at $3.82 on Dec. 10, 2013. Following this transaction, the Director owned 296,800 shares meaning that the stake was reduced by 3.49% with the 10,000-share transaction.

The shares most recently traded at $4.00, up $0.18, or 4.5% since the insider transaction. Historical insider transactions for Halcon Resources go as follows:

  • 4-Week # shares bought: 242,500
  • 12-Week # shares bought: 287,500
  • 24-Week # shares bought: 6.2 million

The average volume for Halcon Resources has been 6.1 million shares per day over the past 30 days. Halcon Resources has a market cap of $1.7 billion and is part of the basic materials sector and energy industry. Shares are down 41.91% year-to-date as of the close of trading on Tuesday.

Halcon Resources Corporation, an independent energy company, engages in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States. Currently there are 7 analysts that rate Halcon Resources a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HK - FREE

TheStreet Quant Ratings rates Halcon Resources as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Halcon Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AptarGroup (ATR) - FREE Research Report

Fourment Olivier who is Segment President at AptarGroup sold 13,000 shares at $64.07 on Dec. 10, 2013. Following this transaction, the Segment President owned 0 shares meaning that the stake was reduced by 100% with the 13,000-share transaction.

The shares most recently traded at $63.77, down $0.30, or 0.48% since the insider transaction.

The average volume for AptarGroup has been 210,200 shares per day over the past 30 days. AptarGroup has a market cap of $4.3 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 34.7% year-to-date as of the close of trading on Tuesday.

AptarGroup, Inc. engages in the design, development, manufacture, and sale of consumer product dispensing systems in North America, Europe, Asia, and Latin America. The company operates in three segments: Beauty + Home, Pharma, and Food + Beverage. The stock currently has a dividend yield of 1.55%. The company has a P/E ratio of 25.8. Currently there are 2 analysts that rate AptarGroup a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATR - FREE

TheStreet Quant Ratings rates AptarGroup as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full AptarGroup Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Actavis (ACT) - FREE Research Report

Stewart Robert A who is Pres-Global Operations at Actavis sold 8,000 shares at $166.02 on Dec. 10, 2013. Following this transaction, the Pres-Global Operations owned 41,253 shares meaning that the stake was reduced by 16.24% with the 8,000-share transaction.

The shares most recently traded at $145.10, down $20.92, or 14.42% since the insider transaction. Historical insider transactions for Actavis go as follows:

  • 12-Week # shares sold: 6,200
  • 24-Week # shares sold: 145,976

The average volume for Actavis has been 1.1 million shares per day over the past 30 days. Actavis has a market cap of $18.6 billion and is part of the health care sector and drugs industry. Shares are up 62.01% year-to-date as of the close of trading on Monday.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally.

Exclusive Offer: Get the latest Stock Analysis on ACT - FREE

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Bitcoin Today: Prices Rally Ahead of Chinese New Year, Moody's Weighs in on Risk

Bitcoin Today: Prices Rally Ahead of Chinese New Year, Moody's Weighs in on Risk

What Happens Next to the Stock Market After Tuesday's Horrid Bloodbath?

What Happens Next to the Stock Market After Tuesday's Horrid Bloodbath?

Bitcoin Today: Price Predictions Get Bold, Nasdaq Considers New Futures Market

Bitcoin Today: Price Predictions Get Bold, Nasdaq Considers New Futures Market

Warren Buffett: Bitcoin 'Will Definitely Come to a Bad Ending'

Warren Buffett: Bitcoin 'Will Definitely Come to a Bad Ending'

8 Great Financial Stocks for 2018

8 Great Financial Stocks for 2018